Lymphocyte Subset Panel 2 - CD4 Percent and Absolute
0095885
Ordering Recommendation
Absolute CD4 count is sufficient for routine HIV monitoring.
Mnemonic
CD4
Methodology
Quantitative Flow Cytometry
Performed
Sun-Sat
Reported
1-2 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
- Patient Preparation
- Collect
- Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin). Hemogard tubes are preferred for laboratory automation and safety.
- Specimen Preparation
- Transport 4 mL whole blood. (Min: 0.5 mL)
- Storage/Transport Temperature
- CRITICAL ROOM TEMPERATURE.
- Unacceptable Conditions
- Clotted or hemolyzed
- Remarks
- Specimens must be analyzed within stability times provided. Some medications may affect immunophenotyping results
and should be listed on the patient test request form.
This test is not approved for New York State Clients. - Stability
- EDTA: Ambient: 72 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
Heparin: Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
Reference Interval
Effective November 16, 2015
Reference Interval Tables:
Pediatric reference values (0 - 6 days up to 10 - 15 years) taken from Scandinavian Journal of Immunology 2012; 75, 436-444.
Adult and Geriatric (16 - 64 and 65 plus years) ranges were developed in-lab.
Reference Interval Tables:
Pediatric reference values (0 - 6 days up to 10 - 15 years) taken from Scandinavian Journal of Immunology 2012; 75, 436-444.
Adult and Geriatric (16 - 64 and 65 plus years) ranges were developed in-lab.
| Test Number | Components | 0-6 days | 1 week - 1 month | 2-4 months | 5-8 months | 9-14 months | 15-23 months | 2-4 years | 5-9 years | 10-15 years | 16-64 years | 64 years or older |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % CD4 | 26-62 % | 39-69 % | 37-69 % | 27-81% | 25-86% | 16-91% | 25-66% | 26-61% | 20-65% | 32-64% | 35-68% | |
| Absolute CD4 | 1000-4800 cells/µL | 1500-6000 cells/µL | 1600-6500 cells/µL | 1000-7200 cells/µL | 1300-7100 cells/µL | 400-7200 cells/µL | 500-2700 cells/µL | 400-2500 cells/µL | 400-2100 cells/µL | 430-1800 cells/µL | 490-1600 cells/µL |
Interpretive Data
The CD4 cells are Helper T-cells expressing both CD3 and CD4. CD4 percentage is reported as a percent of total lymphocytes. CD4 T-cells levels are a criterion for categorizing HIV-related clinical conditions by CDC's classification system for HIV infection. The measurement of CD4 T-cell levels has been used to establish decision points for initiating P. jirovecii prophylaxis, antiviral therapy and to monitor the efficacy of treatment. The Public Health Service (PHS) has recommended that CD4 T-cell levels be monitored every 3 to 6 months in all HIV-infected persons.
Statement B: Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
This test is designed for enumerating the percent and absolute cell count of CD4 Helper T-cells in lysed whole blood. Whole blood is added to fluorochrome-labeled antibodies that bind specifically to cell surface antigens on lymphocytes. After incubation, lysing and fixation, percent and absolute counts are enumerated utilizing an internal quantitation standard. Additional CBC data is not required.
During HIV infection, antiviral therapy is often initiated when the absolute CD4 count drops below 500 cells/µL. When the absolute CD4 count drops below 200 cells/µL, therapeutic prophylaxis against PCP and other opportunistic infections may be initiated. When the absolute CD4 count drops below 100 cells/µL, prophylaxis against Mycobacterium avium complex is recommended.
For longitudinal studies involving serial monitoring, specimen collections should be performed at the same time of day.
During HIV infection, antiviral therapy is often initiated when the absolute CD4 count drops below 500 cells/µL. When the absolute CD4 count drops below 200 cells/µL, therapeutic prophylaxis against PCP and other opportunistic infections may be initiated. When the absolute CD4 count drops below 100 cells/µL, prophylaxis against Mycobacterium avium complex is recommended.
For longitudinal studies involving serial monitoring, specimen collections should be performed at the same time of day.
Hotline History
N/A
CPT Code(s)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0095621 | Lymphocyte Subset Panel 2 Information | 45265-6 |
| 0095906 | Absolute CD4 | 24467-3 |
| 2012857 | % CD4 | 8123-2 |
Aliases
- CD4
- CD4 and absoute Count
- Helper T-Cell level
- Immune Status-Flow Cytometry
- P. jiroveci prophylaxis determination